These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 38888461

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Delayed immune-related adverse events in long-responders of immunotherapy: a single-center experience.
    Kitano M, Honda T, Hikita E, Masuo M, Miyazaki Y, Kobayashi M.
    Asia Pac J Clin Oncol; 2024 Aug; 20(4):463-471. PubMed ID: 38608154
    [Abstract] [Full Text] [Related]

  • 7. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
    Yang F, Shay C, Abousaud M, Tang C, Li Y, Qin Z, Saba NF, Teng Y.
    J Exp Clin Cancer Res; 2023 Jan 05; 42(1):4. PubMed ID: 36600271
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence.
    Xu H, Feng H, Zhang W, Wei F, Zhou L, Liu L, Zhao Y, Lv Y, Shi X, Zhang J, Ren X.
    Exp Cell Res; 2022 Jul 01; 416(1):113157. PubMed ID: 35427598
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K, Nakamura T, Abe T, Ogusu S, Nakashima C, Takahashi K, Kimura S, Sueoka-Aragane N.
    Thorac Cancer; 2019 Sep 01; 10(9):1798-1804. PubMed ID: 31328416
    [Abstract] [Full Text] [Related]

  • 18. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L.
    Oncologist; 2019 Aug 01; 24(8):1128-1136. PubMed ID: 31015312
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
    Zhao Z, Zhang W, Pang L, Zeng L, Liu S, Liu J.
    Front Immunol; 2023 Aug 01; 14():1166299. PubMed ID: 37359551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.